Adaptimmune Therapeutics Plc (ADAP) — Capital Reinvestment Ratio
Adaptimmune Therapeutics Plc (ADAP) has a Capital Reinvestment Ratio of 0.02x as of June 2024, meaning it reinvests 0% of its operating cash flow ($47.39 Million) in capital expenditures ($754.55K). Check ADAP tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Adaptimmune Therapeutics Plc Capital Reinvestment Ratio (2013–2021)
This chart tracks Adaptimmune Therapeutics Plc's Capital Reinvestment Ratio across 2 annual periods. For the full cash flow conversion analysis, see Adaptimmune Therapeutics Plc cash conversion from operations.
Annual Capital Reinvestment Ratio for Adaptimmune Therapeutics Plc (2013–2021)
Year-by-year Capital Reinvestment Ratio for Adaptimmune Therapeutics Plc from 2013 to 2021. See Adaptimmune Therapeutics Plc free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2021 | 0.82x | $10.73 Million | $8.78 Million | ▲ +2002.4% |
| 2013 | 0.04x | $37.23 Million | $1.45 Million | — |